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Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This 
has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID- 19), but repurposed 
antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures 
at studied doses. Nitazoxanide is a US Food and Drug Administration (FDA) approved antiparasitic medicine, that 
physiologically- based pharmacokinetic (PBPK) modeling has indicated may provide antiviral concentrations across 
the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) 
an open label, adaptive, phase I trial in healthy adult participants was undertaken with high- dose nitazoxanide. 
Participants received 1500 mg nitazoxanide orally twice- daily with food for 7 days. Primary outcomes were safety, 
tolerability, optimum dose, and schedule. Intensive pharmacokinetic (PK) sampling was undertaken day 1 and 5 
with minimum concentration (Cmin) sampling on days 3 and 7. Fourteen healthy participants were enrolled between 
February 18 and May 11, 2021. All 14 doses were completed by 10 of 14 participants. Nitazoxanide was safe and 
with no significant adverse events. Moderate gastrointestinal disturbance (loose stools or diarrhea) occurred in 8 
participants (57.1%), with urine and sclera discoloration in 12 (85.7%) and 9 (64.3%) participants, respectively, 
without clinically significant bilirubin elevation. This was self- limiting and resolved upon drug discontinuation. PBPK 
predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Nitazoxanide is an anti- parasitic medication licensed by the 
US Food and Drug Administration (FDA) at standard dosing 
(500 mg b.i.d.) with an established safety profile. Antiviral ac-
tivity has been demonstrated for numerous viruses with in vitro 
data demonstrating activity against severe acute respiratory 
syndrome- coronavirus 2 (SARS- CoV- 2). No steady- state phar-
macokinetic (PK) data are available at higher doses or in coro-
navirus disease 2019 (COVID- 19) but physiologically- based PK 
modeling has indicated a 1500 mg b.i.d. regimen will achieve 
required SARS- CoV- 2 plasma effective concentration 90% 
(EC90) concentrations across the dosing period.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Is high- dose nitazoxanide safe and well- tolerated in healthy 
individuals and can it achieve and maintain plasma antiviral con-
centrations predicted to be sufficient to prevent maturation of the 
SARS- CoV- 2 spike protein and therefore drive antiviral efficacy?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 Plasma concentrations of tizoxanide, the major circulating 
form of nitazoxanide, are sufficient to maintain the in vitro 
derived EC90 and can be safely achieved in healthy individuals. 
The 1,500 mg b.i.d. dose has acceptable tolerability, with mild 
gastrointestinal side effects in healthy volunteers.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 This phase Ia study precedes a seamless phase Ib/IIa evalu-
ation of high dose nitazoxanide in mild/moderate COVID- 19 
within the AGILE platform. It has provided key information 
on the PK profile and tolerability at higher doses that supports 
its evaluation in patients with COVID- 19 and potential use as 
an antiviral in other diseases. These doses will give the maxi-
mal opportunity to achieve antiviral concentrations for SARS- 
CoV- 2 but the efficacy of nitazoxanide for COVID- 19 can only 
be determined in subsequent trials in patients.
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concentration on the first dose and maintained throughout. Nitazoxanide administered at 1,500 mg b.i.d. with food 
was safe with acceptable tolerability a phase Ib/IIa study is now being initiated in patients with COVID- 19.
Since the emergence of coronavirus disease 2019 (COVID- 19) 
in Wuhan, China, in 2019, numerous treatment candidates have 
been tested in late- phase clinical trials. To date, limited thera-
peutic options1 exist, such as steroids and IL- 6 receptor blockers 
(tocilizumab and sarilumab) as immunodulators in severe disease, 
and emerging signals of efficacy of antiviral monoclonal antibody 
therapies. Repurposing of approved drugs is in principle the fast-
est way to establish interventions during an urgent public health 
crisis. This has yielded interventions for severe COVID- 19, but ef-
forts to establish repurposed antiviral interventions have not been 
successful to date. Reasons for failure are multifaceted and relate 
to the pharmacokinetics (PKs) and pharmacodynamics of the can-
didate antiviral drugs. In terms of PKs, most putative repurpos-
ing drugs that have been studied preclinically are not expected to 
reach systemic antiviral concentrations at the approved dose and 
schedule.2 Redundancy of the expected mechanism of action in 
vivo has also been reported, which was driven by inadequacy of the 
in vitro model used to demonstrate activity. For example, the pri-
mary mechanism of antiviral activity for hydroxychloroquine in 
Vero cells involved a process for viral entry, which is secondary in 
vivo. As such, hydroxychloroquine activity is mitigated in animal 
models and in cells expressing TMPRSS2.3,4
Nitazoxanide is a thiazolide US Food and Drug Administration 
(FDA) approved antiparasitic medicine used for the treatment 
of cryptosporidiosis and giardiasis5 and has also reported activity 
against anaerobic bacteria, protozoa, and several other viruses.6 
Rapid deacetylation of nitazoxanide in blood means that the major 
systemic species of the drug in vivo is tizoxanide. Tizoxanide has 
been shown to exhibit similar in vitro inhibitory activity to ni-
tazoxanide for rotaviruses,7 hepatitis B and C viruses,8,9 corona-
viruses other than severe acute respiratory syndrome- coronavirus 
2 (SARS- CoV- 2) and noroviruses.10,11 It has also demonstrated 
in vitro activity against influenza viruses12,13 and in a phase IIb/
III trial in uncomplicated influenza, nitazoxanide demonstrated 
a reduction in symptoms and viral shedding at a dose of 600 mg 
twice- daily compared with placebo,14 despite these doses provid-
ing systemic concentrations that are only expected to remain above 
the influenza in vitro target for a fraction of the dosing interval.2 
Similarly, several recent small clinical trials have indicated some an-
tiviral and clinical benefits of nitazoxanide but at doses that are not 
expected to maintain concentrations above the in vitro antiviral tar-
get for the full dosing interval.15– 17 Although this is encouraging, 
higher doses and combinations are likely to be ultimately needed 
to maximize the antiviral activity and mitigate the risk of emer-
gence of drug resistance.18,19 The antiviral mechanism of action 
of nitazoxanide against influenza involves an impact upon post- 
translational modification and maturation of hemagglutinin,20 and 
a similar mechanism involving the SARS- CoV- 2 spike protein was 
also recently reported.21
Other potential benefits of nitazoxanide in COVID- 19 may 
derive from its impact upon the innate immune response that 
potentiates the production of type 1 interferons13,22 and bron-
chodilation of the airways through inhibition of TMEM16A ion 
channels.23 Moreover, a recent study indicated that drugs which 
inhibit TMEM16, like nitazoxanide, block the SARS- CoV- 2 spike 
protein- mediated syncytia formation via a mechanism independent 
of their antiviral activity.24 At conventional doses of 500 mg twice 
daily, nitazoxanide achieves Ctrough plasma concentrations close 
to the in vitro defined target concentration for SARS- CoV- 2,25 
and exhibits antiviral activity in cell types that recapitulate in vivo 
mechanism of replication.15 The highest nitazoxanide dose re-
ported to date in COVID- 19 clinical trials is 1,000 mg twice- daily, 
utilized in combination with another agent.
Published physiologically- based PK (PBPK) modeling, val-
idated against tizoxanide PKs after single doses ranging between 
500 and 4,000 mg as well as twice daily doses of 0.5 and 1 g, in-
dicated doses above those already approved may provide Ctrough 
above the antiviral target in the majority of patients.2 Modeling 
estimated that 1,400 mg twice- daily or 900 mg 3- times daily will 
provide pulmonary exposures for the entire dosing interval above 
the reported in vitro effective concentration 90% (EC90) for SARS- 
CoV- 2 in over 90% of the population. Nitazoxanide has an estab-
lished safety record in humans and studies showed tolerability of 
single oral doses up to 4,000 g with minimal gastrointestinal (GI) 
side effects. In a separate study involving 16 healthy men, doses of 
either 500 mg twice- daily or 1,000 mg twice- daily for 7 days, the 
500 mg dose was well- tolerated with only mild adverse events not 
differing significantly from the placebo.26 The 1,000 mg twice- daily 
dose was associated with an increased frequency of GI side effects, 
primarily diarrhea and abdominal discomfort, but no significant 
changes were noted in the safety parameters and laboratory tests.
The combination of a long- established safety track record along 
with its demonstrated in vitro activity against coronaviruses, including 
SARS- CoV- 2, and its availability from global generic manufacturers 
at extremely low cost, makes nitazoxanide an attractive therapeutic 
option for dose escalation and repurposing. As such, it was prioritized 
for evaluation at higher doses within the AGILE clinical trial plat-
form, as a potential therapeutic for mild/moderate disease.
METHODS
Study design
This was a single- center, open label, adaptive, phase I trial in healthy adult 
participants (NCT04746183). This was undertaken as a candidate spe-
cific trial within AGILE; a phase Ib/IIa platform trial for evaluating new 
therapies for COVID- 19 (www.agile trial.net), comprising an over- arching 
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Master Protocol27 under which sits candidate- specific trials evaluating 
specific compounds. The study protocol was reviewed and approved by the 
UK Medicines and Healthcare products Regulatory Agency (MHRA) 
and West Midlands Edgbaston Research Ethics Committee. The study 
was coordinated by the National Institute for Health Research (NIHR) 
Southampton Clinical Trials Unit with participants recruited into the 
NIHR Royal Liverpool and Broadgreen Clinical Research Facility (UK).
Participants
Eligible participants included healthy adult men and nonpregnant and 
nonlactating women between 18 and 75 years of age. Women of child-
bearing potential and men (who are sexually active with female partners 
of childbearing potential) were required to use two effective methods 
of contraception, one of which should be highly effective, through-
out the study and for 50 days (women) and 100 days (men) thereafter. 
Participants were included if they were confirmed to be healthy in the ab-
sence of any clinically significant cardiovascular, respiratory, GI, neuro-
logical, psychiatric, metabolic, endocrine, renal, hepatic, hematological, 
or other major disorder. Specific exclusion criteria included: pregnancy 
or currently lactating, being in receipt of any medication, including 
St. John’s Wort, known to chronically alter drug absorption or elimi-
nation within 30 days prior to first dose administration. In particular, 
owing to the high protein binding of tizoxanide; warfarin, phenytoin, 
amiodarone, and intravenous chemotherapy were specifically prohibited 
within 30 days or 5 half- lives (whichever was longer) of first dose admin-
istration and up to the end of the study. Participants in receipt of any 
prescribed medication that required dose alteration or any nonprescribed 
systemic or topical medication, herbal remedy, or vitamin/mineral sup-
plementation within 14 days prior to the first dose administration (un-
less, in the opinion of the investigator, it would not interfere with study 
procedures or compromise safety) were specially excluded. Additionally, 
those with any clinically significant allergy or those that had previously 
received nitazoxanide or its constituent parts within 3 months of receiv-
ing first dose. All participants provided written informed consent before 
enrollment. The full list of inclusion and exclusion criteria can be found 
in Table S1. The flow of participants is outlined in Figure 1.
Model refinement based upon phase I steady- state 
pharmacokinetic data
The PK parameters used for the model construction were obtained 
from a previous publication (Table  S2).28 The initial prediction was 
made using this PBPK model that was validated against steady- state 
PKs at 500 and 1,000  mg b.i.d. and the trial outcome demonstrated 
greater accumulation of drug at steady- state for 1,500  mg b.i.d., with 
higher Ctrough than was predicted from previous studies with 500 and 
1,000  mg  b.i.d.26  Because nitazoxanide has been proposed as a broad- 
spectrum antiviral and also has unrelated suggested utility in several 
noncommunicable diseases, the model was refined so as to be valuable 
for future dose predictions. For this, the absorption rate constant (Ka) 
was adjusted to fit the steady- state 1,500 mg b.i.d. PKs as follows:
where nod is an integer that stands for the number of doses at time t.
The above equation evaluates the value of Ka at every time point as the 
number of doses (nod) increase until it reaches 4 and then remains con-
stant until the end of the simulation period.
Dosing
Eligible participants received 1,500 mg nitazoxanide orally with food, 
twice- daily for 7 days. Dosing with food was undertaken on the inpa-
tient unit on day 1 and day 5; the remaining dosing was administered by 
the participants at home with instruction to eat within 30 minutes of 
dosing. In this study, we had predefined 3 possible dosing strategies for 
nitazoxanide: (1) 1,500 mg 12 hourly (“b.i.d. dosing”), which was pre-
dicted by our PK models to achieve the desired target concentrations, 
plus a further 2 regimens of (2) 1,000 mg 8 hourly (“t.i.d. dosing”), and 
(3) 1,500 mg in the morning, 2,000 mg in the evening (“asymmetric 
dosing”). A Safety Review Committee (SRC) was planned to review 
the initial regimen (1,500 mg b.i.d.) and if deemed a failure because of 
toxicity or failure to achieve target plasma concentrations could rec-
ommended progression to the 1,000 mg t.i.d. and/or asymmetric dose 
cohorts. If the SRC considered a regimen as safe with an achievement 
of target plasma concentrations, they could recommend its further in-
vestigation in a future phase Ib/IIa trial in patients with COVID- 19.
Study procedures
Viral polymerase chain reaction swab screening to exclude COVID- 19 
was performed for all participants 48- hours prior to admission to the 
unit. General physical examination, serum chemistry, and hematology 
sampling were performed at screening, 48  hours prior to dosing, day 
1 baseline, and 72 and 120 hours postdose followed by the final study 
visit at day 14 post- first dose. Urinalysis was performed at screening, 
48 hours predose, 72 hours postdose, followed by the final study visit 
at day 14 post- first dose. Adverse events (AEs) were collected from the 
time of start of the first dose and throughout the study period. For GI 
tolerance, the safety focus point was stool frequency and consistency 
assessed according to the Bristol Stool Chart (BSC).
Outcomes
The primary outcome for this study was to assess safety, tolerability, 
optimum dose, and dosing schedule of nitazoxanide in healthy par-
ticipants through the following parameters: AEs, general physical ex-
amination, general safety assessments, including electrocardiogram 
(ECG), vital signs, clinical laboratory analysis, including urinalysis, he-
matology, and serum chemistry. Because GI intolerance was anticipated 
at the high doses of nitazoxanide used, participants were asked to fill in 
a BSC for the duration of assessment. The primary end point for this 
trial was safety and tolerability defined by AE frequency and severity of 
nitazoxanide in healthy volunteers assessed over 10 days.
Unacceptable safety and tolerability parameters were defined as:
• A treatment emergent serious AE (SAE) in one subject that was 
considered by the investigator to be related to the study drug.
• Two or more AEs, the clinical severity of which was graded by the 
investigator as 3 (severe), 4 (life threatening), or 5 (resulting in 
death).
(1)ka = ka ∗ (1 − 0.05 ∗ nod)
Table 1 Estimated toxicity for nitazoxanide up to day 10 from the POCRM model (for ordering 3)
Dose level
Estimated DLT rate  
(95% Credible interval)
Target dose probability,  
5– 15% DLT rate
Probability of being overly toxic, 
toxicity > 20%
1,500 mg b.i.d. 2.1% (0.0– 14.4%) 11.8% 0.9%
1,000 mg t.i.d. 0.2% (0.0– 2.1%) 0.6% 0.0%
Asymmetric 9.0% (0.0– 36.2%) 26.6% 15.2%
DLT, dose- limiting toxicity; POCRM, Partial Ordering Continual Reassessment Method.
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• Two or more participants in a cohort required withdrawal due to 
elevated alanine aminotransferase (ALT) levels:
ο Asymptomatic elevation in ALT or aspartate aminotransferase 
to more than 3- times the upper limit of normal (ULN), con-
firmed by a repeat measurement within 48 to 72 hours, accompa-
nied by either direct bilirubin level more than or equal to 2- times 
the ULN or International Normalized Ratio (INR) more than 
or equal to 1.5, confirmed with repeat measurement within 
48– 72 hours.
ο Symptomatic elevation in ALT to more than 3- times the ULN.
• Significant diarrhea, defined as 7 or more episodes, rated greater 
than or equal to five on the BSC, in 1 day for 2 consecutive days was 
seen in 2 or more participants in a group.
Additional participant withdrawal criteria included:
• Any clinically relevant signs or symptoms that, in the opinion of the 
investigator, warrant participant withdrawal.
• QTcB prolongation to > 500 milliseconds or a rise in QTcB value 
of > 60 milliseconds (whichever was lower), observed on triplicate 
ECGs, compared with the baseline mean QTcB.
• Positive urine drugs of abuse screen, alcohol breath test, or preg-
nancy test result.
Pharmacokinetic analysis
Intensive plasma PK sampling for tizoxanide and tizoxanide glucu-
ronide was undertaken on day 1 and day 5. Blood samples were col-
lected predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12  hours after first dose 
administration. Additional Ctrough PK samples were obtained at 12- 
hours postdose on days 3 and 7. Tizoxanide and tizoxanide glucuro-
nide concentrations in plasma were measured using a validated liquid 
chromatography tandem mass spectrometry method. In brief, analytes 
were extracted from plasma by protein precipitation with 0.1% for-
mic acid in acetonitrile, centrifuged, and diluted in a reconstitution 
solution (5  mM ammonium formate: acetonitrile, 50:50 v/v) before 
injection onto the high- performance liquid chromatography column. 
Deuterated (D4) internal standards were used and chromatographic 
separation was achieved using a reverse phase C18 column. The calibra-
tion range was linear between 50 and 45,000 ng/mL for both analytes. 
As per protocol, PK success in the trial was defined as median Ctrough 
values above the 1.43  mg/L derived from the in vitro EC90 against 
SARS- CoV- 2.
The combined parent tizoxanide and tizoxanide- glucuronide me-
tabolite dataset was fitted with a parent- metabolite PK model using 
one- compartment disposition for both tizoxanide and tizoxanide- 
glucuronide, with first order absorption/appearance for tizoxanide. 
The model is similar to previous parent- metabolite PK models applied 
for example to rifapentine29 and a schematic and rate equations are 
provided in Figure S1. In the absence of definitive mass balance data 
for fraction of total parent drug clearance accounting for the forma-
tion route of the glucuronide metabolite, apparent clearance (CLmet), 
and Vmet parameters were estimated for the metabolite. Fitting of this 
PK model to the observed plasma concentration data was carried out 
in the R programming environment (version 4.0.3)30 making use of 
the Pracma library31 and lsqnonlin function for nonlinear regression, 
treating the dataset from all participants as a naïve pool. When further 
data become available at the current dose, this PK model can be applied 
using a nonlinear- mixed effects population approach for characteriza-
tion of interindividual variability and potential covariate relationships 
with PK parameters.
In previously published work, a PBPK model was validated for nitazox-
anide using Simbiology (MATLAB R2019a; MathWorks, Natick, MA, 
USA) and used to inform dose selection for the current trial.28 Therefore, 
a comparison was made between the observed PKs in the trial and the a 
priori validated PBPK model prediction.
Statistical analysis
We utilized a Bayesian adaptive design to support decision making in 
this phase Ia study. Details are provided in Supplementary Material. 
Briefly, there was uncertainty about the order of some of the dosing strat-
egies, with respect to their toxicity. To enable us to relax the assumption 
of monotonicity of toxicity, we used the Partial Ordering Continual 
Reassessment Method (POCRM) design proposed by Wages et al.32 ad-
justed to the AGILE setting.
The POCRM utilizes a simple, one- parameter logistic dose- toxicity 
model, which describes the relationship between dose- limiting toxici-
ties (DLTs) within 10  days of initiating treatment and treatment dose 
(1,500 mg b.i.d., 1000 mg t.i.d., and asymmetric dosing) and includes the 
uncertainty about orderings in the working model itself. For each possible 
ordering, the POCRM fits a continual reassessment method model and 
finds the posterior probability of each ordering being the true ordering. 
The model that is deemed the most likely one given the data observed is 
used for the escalation/de- escalation decisions. The prior distributions for 
the POCRM were calibrated to maximize the proportion of correct se-
lection under the range of possible orderings and dose- toxicity scenarios 
within each ordering, where each dose strategy considered in the study 
was the optimum one.
At the end of the cohort, the SRC reviewed all available safety data, in-
cluding at least 10 days data for each participant in the cohort, including 
data on AEs, vital signs, ECGs, and clinical laboratory evaluations, as well 
as any emerging data from other studies. Following SRC review, recom-
mendations could be to de- escalate, escalate, remain at the same dose, or 
continue to phase Ib. A dose was deemed to be unsafe if there was a ≥ 25% 
chance that treatment was associated with a > 20% risk of DLTs at day 10. 
The model recommended the next dose- level according to which level is 
the most likely to correspond to the DLT rate of 5– 15%. However, the 
SRC made the ultimate decision whether to accept that the current dose 
was safe and met the target median Ctrough value of 1.43 mg/L.
All analyses are reported according to CONSORT 2010 and 
International Conference on Harmonization (ICH) E9 guidelines on 
Statistical Principles in Clinical Trials. All enrolled participants were in-
cluded in both the evaluable population and the safety population for anal-
ysis. Statistical analysis was undertaken in SAS version 9.4, STATA version 
16, and R version 4.0.2. Baseline demographics and AEs are summarized 
using descriptive statistics. The estimated DLT rates for each dose strategy 
and equal- tail 95% credible intervals taken from the model of the most 
likely ordering in Table 1. For active doses, we also present the probability 
that the DLT rate falls within 5– 15% (a predetermined acceptable target 
range for toxicity) and the probability of at least 20% toxicity (deemed as 
unacceptably toxic).
The sample size was flexible, based on the need for the study to adapt to 
accruing safety data. Simulations to assess model operating characteristics 
and to calibrate priors assumed 3 possible orderings and the same three 
dose strategies within each ordering, with cohorts of size 12 capped at a 
total of 36 participants.
RESULTS
Between February 18 and May 11, 2021, 14 healthy volunteers 
received at least one dose of nitazoxanide (Table  S3.) Of 14 
participants dosed, 10 of 14 (71.4%) completed 7 full days of 
dosing (14 doses). Four participants discontinued dosing as a 
result of an artifactual QTcB prolongation occurring in one 
participant, which led to suspension of dosing in the entire co-
hort. Four of 14 participants discontinued dosing early; 2 of 4 
discontinued after 6 full days (12/14 doses), and the remaining 
2 of 4 discontinued after 1 full day (2/14 doses). All 14 partici-
pants were included in the safety and PK analyses. The f low of 
trial participants is shown in Figure 1. The demographics and 
clinical characteristics at baseline are summarized in Table 2.
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Safety results
Nitazoxanide was safe with acceptable tolerance at 1,500 mg twice 
daily for 7 days with no significant AEs (Table 3). Moderate GI 
disturbance (sufficient to interfere with daily activities) was seen 
in three participants (21.4%) with a further eight participants 
(57.1%) experiencing mild GI symptoms (covering a spectrum of 
nausea, bloating, constipation, diarrhea or loose stools, and/or ab-
dominal pain). Yellow discoloration of the urine and sclera was 
observed in 12 (85.7%) and 9 (64.3%) participants, respectively, 
without clinically significant elevation in bilirubin. This was 
self- limiting and resolved upon discontinuation of the drug. No 
grade 3 or 4 AEs were documented.
Minor, self- resolving, postdose elevation in creatine kinase (CK) 
was identified in 5 of 14 participants (maximum 869 U/L at D5 
postdose; Table S4). One of the participants reported mild local-
ized myalgia without muscle tenderness at D5 (CK 508 U/L), 
which was recorded as an AE. All other elevations were not consid-
ered clinically significant.
In one participant, tachycardia (heart rate 112  bpm) developed 
shortly after the second dose administration on day 1, with an ECG 
Figure 1 CONSORT diagram. BMI, body mass index; PI, principal investigator.
Assessed for eligibility (n=23) 
Reasons for not enrolling (n=9) 
Prohibited medicaon (n=1) 
Abnormal labs (n=1) 
Not in good health (n=1) 
Not within BMI range (n=1) 
Parcipant choice (n=3) 
Cohort full (n=2) 
Enrolled (n=14) 
Cohort 1: 1500mg BID (n=14):
Received at least one dose of IMP (n=14) 
Received all planned doses of IMP (n=10) 
Completed treatment (n=10) 
Reasons for IMP disconnuaon: 
o PI withdrawal of subject from treatment - due
to cohort stopping criteria (n=4)
Included in evaluable populaon (n=14) 
Included in safety populaon (n=14) 
Cohort 1: 1500mg BID (n=14): 
Completed study (n=14) 
Length of follow-up: 
o Median: 14 days
o Range: 14 – 41 days
Table 2 Participant demographics and characteristics
Characteristics Statistic
Nitazoxanide (1,500 mg twice- daily, 
n = 14)
Age Median (range) 25 (19– 53)
Sex Male/female % 35.7%/64.3%
Ethnicity White- English/Welsh/Scottish/Northern Irish/British 9 (64.3%)
Any other White background 3 (21.4%)
Any other Asian background 2 (14.3%)
Body weight (kg) Median (range) 65.6 (61.2– 96.3)
BMI (kg/m2) Median (range) 23.9 (19.3– 30.8)
BMI, body mass index.
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recorded 7 minutes following the second dose showing a corrected 
QTcB (using Bazett’s formula) of 468  msec, an apparent increase 
of 73.5 msec above the mean baseline (394.5  msec; Figure  S2). 
Treatment was discontinued in all being dosed. Following overnight 
admission for observation and serial ECGs (SAE; Table 3), an ap-
parent prolongation recurred at 5 hours and 44 minutes following 
the second dose, 460 msec (65.5 msec above baseline mean, heart 
rate 87 bpm) and resolved fully thereafter. Independent cardiology 
review of all ECGs with manual QT and QTcB calculations con-
firmed an artifactual QTcB increase due to the presence of a prom-
inent U- wave fused with the end of the T wave, causing the ECG 
machine to calculate the QU interval instead of the QT interval. 
Following formal review by the trial SRC and in consultation with 
the UK medicines regulator, the trial (which had been temporarily 
suspended) was reopened at the same dose level with replacement 
of 2 participants who discontinued dosing after only 1 full day. 
Additional ECGs were obtained at 14 hours post first- dose on day 
1 and day 5 for subsequent participants, with no significant changes 
observed.
An updated PBPK model to incorporate changes in steady- 
state pharmacokinetics at higher doses
Figure S3 shows an updated PBPK model for forward prediction 
of steady- state PKs of tizoxanide. The predicted PK parameters 
– Cmax, Ctrough, and area under the curve (AUC) had a ratio < 2 
against the observed data, as shown in the Table S5. The observed 
PKs of tizoxanide at 1,500 mg follow flip- flop kinetics, the addi-
tional equation (Eq.  1) to the absorption phase therefore delays 
the Tmax and increases the Ctrough from day 2 onward. This addi-
tion improved the overall prediction of the steady- state PK with 
little difference between observed and predicted values. High data 
variability across individuals due to limited sample size and dosing 
and/or sampling differences in the observed data may contribute 
to PK differences between observed and simulated data for Ctrough 
at 48 hours and the Tmax on day 5.
Pharmacokinetics and modeling
Median Ctrough at the end of the first dose were above the in vitro- 
defined target concentration (EC90 – 1.43 mg/L) and remained 
so throughout dosing. The simultaneous fitting of the parent- 
metabolite PK model to the tizoxanide and tizoxanide glucuro-
nide datasets is illustrated in Figure 2, with parameter estimates 
and relative standard errors in Table 4. An acceptable description 
of the data was obtained with acceptable precision of estimates. 
Interindividual variability in plasma exposure appears relatively 
wide but may reflect to some extent variability in administration 
times for doses taken by patients at home compared with nominal 
dosing times. The PBPK simulated tizoxanide plasma concen-
trations relative to the naïve pool of data from healthy individu-
als in this study is shown over the 7 days of dosing in Figure 3a. 
Figure 3b and c show the comparison of the observed and sim-
ulated median PK profiles on day 1 and day 5, respectively. The 
corresponding PK data and a numerical comparison between ob-
served and simulated Cmax and Ctrough is provided as Table  S4. 
The trial confirmed prior PBPK predictions for the first dose but 
Table 3 AEs and SAEs
Adverse event (all grades 1 
or 2)
Nitazoxanide (1,500 mg b.i.d.) 
(n = 14)
Urine discoloration 12 (85.7%)
Yellow sclera 9 (64.3%)
Nausea 7 (50.0%)
Abdominal pain 6 (42.9%)
Diarrhea 5 (35.7%)








Flu like symptoms 1 (7.1%)
Loss of appetite 1 (7.1%)
Non- cardiac chest pain 1 (7.1%)
Fall 1 (7.1%)




Irregular menstruation 1 (7.1%)
Semen discoloration 1 (7.1%)
Vaginal discharge 1 (7.1%)
Laryngeal inflammation 1 (7.1%)
Blister on abdomen 1 (7.1%)
Hypotension 1 (7.1%)
Abdominal gas (rumbling) 1 (7.1%)
Elevated creatine kinase 1 (7.1%)
Heavy sensation to eyes 1 (7.1%)
Leg pain/stiffness 1 (7.1%)
Mouth ulcer 1 (7.1%)
Musculoskeletal pain (elbow) 1 (7.1%)
Musculoskeletal pain (hip) 1 (7.1%)
Other – stomach cramps 1 (7.1%)
Rash 1 (7.1%)
Reduced appetite 1 (7.1%)
Shortness of breath 1 (7.1%)
Skin discoloration 1 (7.1%)
Stye (right eye) 1 (7.1%)
Yellow semen 1 (7.1%)






AE, adverse event; SAE, serious adverse event.
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with underprediction of exposures at day 5, with higher PK expo-
sures and delayed Tmax observed clinically than predicted by the 
PBPK modelling. Because the PBPK model was validated against 
the clinical data for multiple b.i.d. doses of 500  mg and 1  g ni-
tazoxanide,26 where no drug accumulation was observed as the 
days progressed, the model was not able to capture appropriately 
the drug accumulation observed with the 1,500 mg b.i.d. regimen 
with an increasing Ctrough from day 1 to day 5 and day 7. However, 
concentrations above the target (i.e., EC90 – 1.43  mg/L) were 
achieved on the first dose and safely maintained throughout the 
course.
DISCUSSION
This study establishes the safety and acceptable tolerance of 
high- dose nitazoxanide with food in healthy adult participants. 
A nitazoxanide dose of 1,500 mg twice- daily for 7 days is safe 
and the plasma concentrations attained are expected to be 
sufficient to achieve the in vitro- defined EC90 against SARS- 
CoV- 2 in over 90% of the population. As expected, GI effects 
were common (predominantly nausea, abdominal discomfort, 
bloating, and loose stools) and at most, of moderate intensity 
(grade 2 discomfort sufficient to cause interference with nor-
mal activities). Participants also reported yellow discoloration 
Figure 2 Simultaneous one- compartment, first order absorption parent- metabolite PK model fitting to naïve pooled tizoxanide (parent) 
and tizoxanide- glucuronide (metabolite) plasma concentration data. The red line represents the in vitro derived EC90 against SARS- CoV- 2 
(1.43 mg/L). Conc, concentration; EC90, effective concentration 90%; GLU, glucuronide; PK, pharmacokinetic; SARS- CoV- 2, severe acute 
respiratory syndrome- coronavirus 2; TIZ, tizoxanide.
Table 4 Parameter estimates for simultaneous parent- metabolite PK model fitting to tizoxanide and tizoxanide glucuronide 
plasma concentration data
CLTIZ/FTIZ, L/h VTIZ/FTIZ, L Ka, h
−1 CLMET/(FTIZ*FMET), L/h VMET/(FTIZ*FMET), L/h
Parameter estimate 3.95 64.99 0.45 5.88 12.71
% RSE* 3.64 8.15 14.20 3.70 12.67
CLMET, metabolite clearance; CLTIZ, tizoxanide clearance; FMET, bioavailability of tizoxanide; FTIZ, tizoxanide glucoronide; Ka, absorption rate constant; PK, 
pharmacokinetic; RSE, relative standard error.
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of sclera and bodily f luids in line with the Summary of Product 
Characteristics and previous reports, and these fully resolved 
upon discontinuation of the drug.
Minor elevation in CK, predominantly in the second half of the 
cohort, was noted in 5 of 14 participants. This was also self- resolving 
and not associated with muscle tenderness on physical examination. 
We believe increased self- reported physical activity of participants, co-
inciding with COVID- 19 lockdown restrictions easing, may explain 
the mild CK elevations observed but ongoing monitoring of CK will 
be undertaken as part of phase Ib in patients with COVID- 19.
Figure 3 Comparison of PBPK simulated and observed tizoxanide plasma concentrations. (a) comparison of median (SD) simulated 
concentrations (blue) against the naïve pool of plasma concentration in healthy individuals. (b) Comparison of observed and simulated median 
(95% CI) tizoxanide plasma concentrations following the first dose. (c) Comparison of observed and simulated median (95% CI) tizoxanide 
plasma concentrations on day 5. The red line represents the in vitro derived EC90 against SARS- CoV- 2 (1.43 mg/L; 5.4 µm). CI, confidence 
interval; EC90, effective concentration 90%; PBPK, physiologically- based pharmacokinetic; SARS- CoV- 2, severe acute respiratory syndrome- 
coronavirus 2; TIZ, tizoxanide.
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After review, the SRC and the AGILE Independent Data 
Monitoring and Ethics Committee agreed that these AEs were 
minor. The POCRM model suggested an escalation to the asym-
metric regimen was safe. However, the preferred starting regi-
men of 1,500 mg b.i.d. was on course to yield optimal exposure 
and was recommended to progress to evaluation in patients with 
COVID- 19 and as such the other two potential dosing cohorts 
did not proceed in this study. An AGILE phase 1b study is now 
being initiated in South Africa for confirmatory PK analysis 
and tolerability in patients with COVID- 19, including alterna-
tive dosing regimens if required, with seamless transition into 
phase IIa.
Selection of the target plasma concentration was based upon an 
in vitro derived EC90 value generated in Vero cells using nitazox-
anide and not tizoxanide.33 However, further in vitro experimen-
tation was conducted internationally because this original report 
has demonstrated similar activity in lung epithelial cell models as 
well as activity of tizoxanide comparable to nitazoxanide itself.34– 36 
Furthermore, the antiviral activity has been confirmed to involve 
inhibition of maturation of the SARS- CoV- 2 spike protein,21 
which is similar to the mechanism of antiviral activity for influ-
enza.37 More recently, a separate and distinct mechanism involv-
ing blocking of spike- mediated syncytia formation via interactions 
with TMEM16 has been reported, which may moderate disease 
severity in parallel to the antiviral effect.24 Target concentrations 
for this secondary mechanism are yet to be clarified but warrant 
further investigation.
The authors highlight the uncertainty around the therapeu-
tic target concentration for tizoxanide that specifically relates 
to the impact of plasma protein binding. Consensus on applica-
tion of protein binding assessments to purported SARS- CoV- 2 
antivirals was published recently in a series of papers in the 
journal.38– 40 It should be noted that drug binding in vitro is al-
most never zero because drugs bind to culture plastics or serum 
proteins present in the culture media, even small amounts of 
culture serum can sometimes bind large amounts of drug, and 
protein binding may be low affinity/high capacity or vice versa 
for different drugs. Therefore, empirically determined protein- 
adjusted activity values are critical to ascertain the compound- 
specific importance of protein binding but are not currently 
available for nitazoxanide.
Although defining the optimal dose and duration of repur-
posed therapeutics is fundamental to later trial success, it cannot 
be assumed that effective doses and exposures directly translate 
into patients with COVID- 19, particularly those with altered 
pathophysiology due to severe illness. This is a limitation of all 
first- in- human healthy volunteer studies, within which it is al-
ways difficult to generate pharmacodynamic data. The median 
age and lack of medical comorbidities in this healthy volunteer 
cohort also differs from the main target population for early use 
of antivirals, although their use in post- exposure prophylaxis and 
to reduce isolation requirements in low- risk groups is also being 
considered.
There is an urgent unmet need for safe and effective antiviral 
therapeutics in early- stage mild/moderate COVID- 19. These 
are aimed at preventing progression of disease to hospitaliza-
tion and death, and possibly also reducing viral transmission 
in community settings. Repurposing and dose escalation of ni-
tazoxanide for COVID- 19 is supported by in vitro data, PBPK 
modeling and now robust safety and PK data at the 1,500  mg 
b.i.d. dose. This dose will provide the maximum potential to 
demonstrate antiviral activity of nitazoxanide in subsequent tri-
als to provide a definitive outcome on the utility of this drug in 
COVID- 19.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
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